Sentrx Surgical, the first spin-out company of the Center for Therapeutic Biomaterials, is an emerging medical device company that is using proprietary modified biopolymers to create synthetic scaffolds that mimic the normal extracellular matrix. This synthetic scaffold can be used to promote scar-free wound healing, engineer new tissues, and prevent post-surgical adhesions.

UU Press Release, September 2004

The company was founded in 2004 by Drs. Glenn Preswich, Richard Koehn, Richard Orlandi and Albert Park.

Sentrx Surgical, Inc. received two Small Business Technology Transfer Research (STTR) awards from the National Institutes of Health (NIH). On September 1, 2004, Sentrx Surgical and the University of Utah signed a license agreement that gives the company exclusive, world-wide rights to the use of a proprietary technology invented by Dr. Glenn Prestwich at the University of Utah.

In December 2005, an investment by InterWest Partners and Alta Partners funded the original Sentrx Surgical as Carbylan BioSurgery, Inc. (Palo Alto, CA) to develop only the human
therapeutic uses of the Utah-based technology.

Highlights

• Synthetic modified biopolymer scaffold can be used to promote scar-free wound healing, engineer new tissues, and prevent post-surgical adhesions.

• Pre-revenue
• 10 FTE's